Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.84 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516641 | 0.93 | HDAC8 (0.73) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL16516649 | 0.92 | HDAC8 (0.72) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL18538449 | 0.92 | HDAC8 (0.71) | HDAC8LY96HDAC3HDAC1ALDH1A1 | |
| SCHEMBL16516744 | 0.92 | HDAC8 (1.00) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL16516237 | 0.86 | HDAC8 (0.89) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL18542270 | 0.86 | LY96 (0.74) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL16516670 | 0.85 | HDAC8 (0.87) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL16516560 | 0.85 | HDAC8 (0.87) | HDAC8LY96HDAC3HDAC1ALDH1A1 | |
| SCHEMBL18538446 | 0.81 | HDAC8 (1.00) | HDAC8LY96BACE1HDAC3HDAC1 | |
| SCHEMBL21064515 | 0.81 | HDAC8 (1.00) | HDAC8LY96BACE1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
| EP-3035924-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | City of Hope (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015026935-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE (US) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885LY96 3343/4885BACE1 3800/4885 |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885LY96 3343/4885BACE1 3800/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885LY96 3343/4885BACE1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.